StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
9686.HK$1.01+2.02%
Fair $1.01+0.0%

9686.HK

Xikang Cloud Hospital Holdings Inc.

Healthcare / Health Information ServicesHKSE

$1.01

+0.02 (+2.02%)

Fairly Valued+0.0%Fair Value $1.01Fund rank 21/100 · Data gapFallback financials|
SA 33/D
F-Score: 4/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $8.1M · quality 27.3/100

Data gap 21/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

33/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. Revenue has declined for 3 consecutive years ROE is -12.4%, below the 5% threshold
Thesis & Journal · 9686.HKLocal privado en este navegador · Xikang Cloud Hospital Holdings Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$850M

P/E

N/A

•

EV/EBITDA

39.2x

↑

ROE

-12.4%

↓

Gross Margin

27.3%

↓

Debt/Equity

1.66

↑
52-Week Range$1
$1$1

TradingView lightweight chart

9686.HK price, volumen y niveles de valoración

Último $1.010Periodo -62.9%
Fair value: $1.010

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-12.3%

FCF CAGR

—

FCF margin

7.6%

FCF / Net income

-0.90x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $464.1M · net income $-38.9M · FCF $35.1M

2022-FY → 2025-FY

Gross margin

27.3%+2.8% pts

Operating margin

-11.8%+11.0% pts

Net margin

-8.4%+26.8% pts

FCF margin

7.6%+19.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$464.1M$464.1M$501.5M$537.7M$687.4M
Net Income$-38.9M$-38.9M$-83.1M$-154.7M$-242.0M
EBITDA$21.0M$21.0M$-28.5M$-75.7M$-161.4M
EPS——-0.10-0.23-0.29
Gross Margin27.3%27.3%29.4%30.6%24.5%
Operating Margin-11.8%-11.8%-7.0%-18.9%-22.8%
Net Margin-8.4%-8.4%-16.6%-28.8%-35.2%
Balance Sheet
Debt/Equity1.661.661.581.41-1.27
Current Ratio1.181.18———
Cash Flow
Free Cash Flow$35.1M$35.1M$8.1M$-24.4M$-81.2M
Returns
ROE-12.4%-12.4%-22.9%-36.1%53.5%
Valuation
EV/EBITDA39.2239.22———
P/B2.712.711.922.12—
Growth & Yield
Revenue Growth-7.4%-7.4%-6.7%-21.8%—
EPS Growth——56.5%20.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +11.0%

Total return

+11.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.10 → n/d

Residual

+11.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+11.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.